Agios Pharmaceuticals (AGIO) Enterprise Value (2013 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Enterprise Value data on file, last reported at -$617.6 million in Q2 2026.

• Quarterly Enterprise Value rose 34.23% year-over-year to -$617.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$617.6 million (up 34.23% YoY) and the FY2025 annual result came in at -$854.4 million, up 4.4% from the prior year.
• Enterprise Value climbed to -$617.6 million in Q2 2026, from -$737.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$569.9 million in Q2 2024 to a low of -$1.0 billion in Q3 2024.
• A 5-year average of -$787.8 million and a median of -$780.0 million in 2022 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2022 — Enterprise Value surged 60.46% — and 2025, when it tumbled 64.76%.
• Tracing AGIO's Enterprise Value over 5 years: stood at -$783.1 million in 2022, then climbed by 0.79% to -$776.9 million in 2023, then retreated by 15.03% to -$893.7 million in 2024, then gained by 4.4% to -$854.4 million in 2025, then gained by 27.72% to -$617.6 million in 2026.
• The last three Enterprise Value figures came in at -$617.6 million (Q2 2026), -$737.0 million (Q1 2026), and -$854.4 million (Q4 2025), per Business Quant data.